Novartis

Ultime notizie

Titoli nella lingua originale della fonte.

• Buccaneer to Host Green Bay Packers in Week 4 Crucial Catch Game, Presented by Novartis (si apre in una nuova scheda)

  Tampa Bay Buccaneers · 2 ott 2026

• Jennifer Brogdon Reflects on Pioneering CAR-T Therapy and Her Next Chapter After 22 Years at Novartis (si apre in una nuova scheda)

  Oncodaily · 2 ott 2026

• Abogen licenses mRNA-encoded T-cell engager to Novartis in deal worth up to $7.8 billion (si apre in una nuova scheda)

  The Pharma Letter · 2 ott 2026

• Novartis signs $7.8 billion drug deal with Chinese startup (si apre in una nuova scheda)

  Axios · 2 ott 2026

• Novartis Licenses Abogen's mRNA-Encoded CD19xCD3 T-Cell Engager ABO2203 for Autoimmune Diseases (si apre in una nuova scheda)

  BioPharm International · 2 ott 2026

• Novartis bets up to $7.8B on Abogen’s mRNA autoimmune therapy (si apre in una nuova scheda)

  European Biotechnology Magazine · 2 ott 2026

• Novartis wagers almost $8B on a Chinese biotech’s RNA drugs (si apre in una nuova scheda)

  BioPharma Dive · 2 ott 2026

• Novartis taps Abogen’s RNA platform in potential $7.8B deal (si apre in una nuova scheda)

  BioWorld News · 2 ott 2026

• Novartis signs up to $7.8B mRNA licensing deal with Abogen (si apre in una nuova scheda)

  Dealroom · 2 ott 2026

• From Novartis to Novo, the big pharma companies are turning to Chinese biotech firms (si apre in una nuova scheda)

  Il Sole 24 ORE · 2 ott 2026

• Novartis India Limited Rebrands as Evonile Pharma Limited Following MCA Approval (si apre in una nuova scheda)

  EquityBulls · 2 ott 2026

• Novartis signs mRNA deal for about $7.8 billion with China’s Abogen (si apre in una nuova scheda)

  pharmalive.com · 2 ott 2026

• Novartis strikes up to $7.8 billion mRNA deal with China's Abogen (si apre in una nuova scheda)

  Reuters · 2 ott 2026

• Novartis bets up to $7.8B for an mRNA-encoded T cell engager from China’s Abogen (si apre in una nuova scheda)

  BioSpace · 2 ott 2026

• Big Pharma is striking more and more deals in China: Novartis will pay up to $7.8 billion (si apre in una nuova scheda)

  LIGA.net · 2 ott 2026

• Roundup: Novartis & Abogen Enter Licensing and Option Agreement, AstraZeneca and Daiichi Sankyo Enter Clinical Collaboration with Summit Therapeutics (si apre in una nuova scheda)

  Pharmaceutical Executive · 2 ott 2026

• Novartis pays Abogen $575m for mRNA programs (si apre in una nuova scheda)

  BioXconomy · 2 ott 2026

• Novartis licenses Abogen mRNA autoimmune drug in $7.8B deal (si apre in una nuova scheda)

  qz.com · 2 ott 2026

• Novartis Signs $7.8 Billion mRNA Therapy Deal with China's Abogen (si apre in una nuova scheda)

  globalbankingandfinance.com · 2 ott 2026

• The Novartis deal could bring Abogen up to USD 7.8 billion (si apre in una nuova scheda)

  Biostock · 2 ott 2026

• Novartis taps China's Abogen for autoimmunity TCE (si apre in una nuova scheda)

  pharmaphorum · 2 ott 2026

• Novartis secures $7.8 billion mRNA deal with China's Abogen to target autoimmune diseases (si apre in una nuova scheda)

  streamlinefeed.co.ke · 2 ott 2026

• Abogen announces licensing, option agreement with Novartis (si apre in una nuova scheda)

  TipRanks · 2 ott 2026

• Novartis to License Drug From China’s Abogen in Up to $7.8 Billion Deal (si apre in una nuova scheda)

  WSJ · 2 ott 2026

• Novartis, China's Abogen Ink $7.8 Billion Deal For mRNA Therapies (si apre in una nuova scheda)

  NDTV Profit · 2 ott 2026

• Novartis strikes $7.8bn deal with Chinese biotech (si apre in una nuova scheda)

  lifesciencefocus.com · 2 ott 2026

• Novartis signs $7.8 billion Abogen RNA licensing deal (si apre in una nuova scheda)

  grafa.com · 2 ott 2026

• Novartis signs Abogen licensing deal worth up to $7.8 billion (si apre in una nuova scheda)

  Traders Union · 2 ott 2026

• Novartis inks $7.8B deal with Chinese biotech f... (si apre in una nuova scheda)

  Pluang · 2 ott 2026

• Novartis bets on autoimmune BiTEs through $7.8bn Abogen deal (si apre in una nuova scheda)

  pharmaceutical-technology.com · 2 ott 2026